International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(4), С. 1396 - 1396

Опубликована: Фев. 7, 2025

Triple-negative breast cancer (TNBC) is the most aggressive and malignant type of with limited treatment options poor prognosis. One significant impediments in TNBC high heterogeneity this disease, as highlighted by detection several molecular subtypes TNBC. Each subtype driven distinct mutations pathway aberrations, giving rise to specific characteristics closely connected clinical behavior, outcomes, drug sensitivity. This review summarizes knowledge regarding how it can be harnessed devise tailored strategies instead blindly using targeted drugs. We provide an overview novel agents key insights about new modalities emphasis on androgen receptor signaling pathway, stem cell-associated pathways, phosphatidylinositol 3-kinase (PI3K)/AKT growth factor signaling, immunotherapy.

Язык: Английский